PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus

Tong,Yin; Zhu,Weiwei; Huang,Xianbo; You,Liangshun; Han,Xiujun; Yang,Chunmei; Qian,Wenbin

doi:10.3892/or.2014.3020

PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus

Authors:
- Yin Tong
- Weiwei Zhu
- Xianbo Huang
- Liangshun You
- Xiujun Han
- Chunmei Yang
- Wenbin Qian
View Affiliations

Affiliations: Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, P.R. China, Women's Hospital, College of Medicine, Zhejiang University, Hangzhou 310006, P.R. China
Published online on: February 11, 2014 https://doi.org/10.3892/or.2014.3020
Pages: 1581-1588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, much progress has been achieved in the treatment of multiple myeloma (MM). However, the major challenge of chemotherapeutic drugs is acquired resistance. Oncolytic virotherapies offer promising alternatives; with the possibility of their integration with current therapeutic strategies. In the present study, we assessed the potential of ZD55-TRAIL (an oncolytic adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand) as an oncolytic agent for MM. Our results clearly indicated that ZD55 armed with TRAIL was more cytotoxic to drug-sensitive as well as drug-resistant MM cell lines, than the virus alone. Furthermore, it was also observed that ZD55-TRAIL induced apoptosis through the activation of the caspase pathway. In particular, ZD55-TRAIL significantly inhibited insulin-like growth factor-1 receptor (IGF-1R) and NFκB. However, IGF did not abrogate ZD55‑TRAIL-induced cell death. Combination of ZD55-TRAIL with the PI3K inhibitor LY294002 in RPMI‑8226 cells inhibited the virus‑mediated activation of mTOR and AKT, thus, promoting cell death. Combined treatment of ZD55-TRAIL and MG132 (a proteasome inhibitor) robustly increased the expression of death receptor 5 (DR5), which enhanced the apoptosis response without significant toxicity to normal liver cells. Collectively, our results suggest that combined treatment of TRAIL-armed oncolytic adenovirus and a PI3K inhibitor or a proteosome inhibitor may serve as a promising therapy for MM.

View Figures

View References

1	Kyle RA: Multiple myeloma: an odyssey of discovery. Br J Haematol. 111:1035–1044. 2000. View Article : Google Scholar : PubMed/NCBI
2	Brenner H, Gondos A and Pulte D: Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010. Haematologica. 94:270–275. 2009.
3	Barlogie B, Attal M, Crowley J, et al: Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 28:1209–1214. 2010. View Article : Google Scholar
4	Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2:927–937. 2002. View Article : Google Scholar : PubMed/NCBI
5	Hellwig CT and Rehm M: TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
6	Herbst RS, Eckhardt SG, Kurzrock R, et al: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gajate C and Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood. 109:711–719. 2007. View Article : Google Scholar : PubMed/NCBI
8	Mitsiades CS, Treon SP, Mitsiades N, et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 98:795–804. 2001. View Article : Google Scholar : PubMed/NCBI
9	Gazitt Y: TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 13:1817–1824. 1999. View Article : Google Scholar : PubMed/NCBI
10	Jazirehi AR, Ng CP, Gan XH, Schiller G and Bonavida B: Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res. 7:3874–3883. 2001.
11	Vitovski S, Chantry AD, Lawson MA and Croucher PI: Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One. 7:e358302012. View Article : Google Scholar
12	Hermiston TW and Kuhn I: Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 9:1022–1035. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zhang ZL, Zou WG, Luo CX, et al: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13:481–489. 2003. View Article : Google Scholar : PubMed/NCBI
14	Dong F, Wang L, Davis JJ, et al: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-α-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res. 12:5224–5230. 2006.PubMed/NCBI
15	Pei Z, Chu L, Zou W, et al: An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 39:1371–1381. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wang SB, Tan Y, Lei W, et al: Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Hum Gene Ther. 23:992–1002. 2012. View Article : Google Scholar : PubMed/NCBI
17	Meng H, Jin Y, Liu H, You L, Yang C, Yang X and Qian W: SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol. 6:182013. View Article : Google Scholar : PubMed/NCBI
18	Chauhan D, Velankar M, Brahmandam M, et al: A novel Bcl-2/Bcl-X_L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 26:2374–2380. 2007.PubMed/NCBI
19	Kuhn DJ, Berkova Z, Jones RJ, et al: Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 120:3260–3270. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tagoug I, Sauty De Chalon A and Dumontet C: Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One. 6:e226412011. View Article : Google Scholar : PubMed/NCBI
21	Ikeda H, Hideshima T, Fulciniti M, et al: PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood. 116:1460–1468. 2010.PubMed/NCBI
22	Maiso P, Liu Y, Morgan B, et al: Defining the role of TORC1/2 in multiple myeloma. Blood. 118:6860–6870. 2011. View Article : Google Scholar : PubMed/NCBI
23	Park S, Chapuis N, Tamburini J, et al: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 95:819–828. 2010. View Article : Google Scholar : PubMed/NCBI
24	Oh WJ and Jacinto E: mTOR complex 2 signaling and functions. Cell Cycle. 10:2305–2316. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG and de Jong S: Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer. 118:1892–1900. 2006. View Article : Google Scholar : PubMed/NCBI
26	Seol DW: p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun. 416:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
27	Bais S, Bartee E, Rahman MM, McFadden G and Cogle CR: Oncolytic virotherapy for hematological malignancies. Adv Virol. 2012:1865122012. View Article : Google Scholar : PubMed/NCBI
28	Raus S, Coin S and Monsurrò V: Adenovirus as a new agent for multiple myeloma therapies: opportunities and restrictions. Korean J Hematol. 46:229–238. 2011. View Article : Google Scholar : PubMed/NCBI
29	Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW and Russell SJ: Curative one-shot systemic virotherapy in murine myeloma. Leukemia. 26:1870–1878. 2012. View Article : Google Scholar : PubMed/NCBI
30	Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR and Barry MA: Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 21:179–190. 2010. View Article : Google Scholar : PubMed/NCBI
31	Chen CY, Senac JS, Weaver EA, et al: Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res. 17:6712–6722. 2011. View Article : Google Scholar : PubMed/NCBI
32	Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
33	Tu Y, Gardner A and Lichtenstein A: The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 60:6763–6770. 2000.PubMed/NCBI
34	Hsu J, Shi Y, Krajewski S, et al: The AKT kinase is activated in multiple myeloma tumor cells. Blood. 98:2853–2855. 2001. View Article : Google Scholar : PubMed/NCBI
35	Bruno B, Giaccone L, Rotta M, Anderson K and Boccadoro M: Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia. 19:1729–1738. 2005. View Article : Google Scholar : PubMed/NCBI
36	Sprynski AC, Hose D, Caillot L, et al: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 113:4614–4626. 2009. View Article : Google Scholar : PubMed/NCBI
37	Huo J, Xu S, Lin B, Chng WJ and Lam KP: Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia. 27:1165–1171. 2013. View Article : Google Scholar : PubMed/NCBI
38	Strömberg T, Ekman S, Girnita L, et al: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 107:669–678. 2006.PubMed/NCBI
39	Thaci B, Ulasov IV, Wainwright DA and Lesniak MS: The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget. 2:113–121. 2011.PubMed/NCBI
40	Tamanini A, Nicolis E, Bonizzato A, Bezzerri V, Melotti P, Assael BM and Cabrini G: Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol. 80:11241–11254. 2006. View Article : Google Scholar : PubMed/NCBI
41	Verdino P, Witherden DA, Havran WL and Wilson IA: The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science. 329:1210–1214. 2010. View Article : Google Scholar : PubMed/NCBI
42	David E, Sinha R, Chen J, Sun SY, Kaufman JL and Lonial S: Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res. 14:5090–5098. 2008. View Article : Google Scholar : PubMed/NCBI
43	Surget S, Chiron D, Gomez-Bougie P, et al: Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res. 72:4562–4573. 2012. View Article : Google Scholar : PubMed/NCBI
44	Voortman J, Resende TP, Abou El Hassan MA, Giaccone G and Kruyt FA: TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 6:2103–2112. 2007. View Article : Google Scholar : PubMed/NCBI
45	Mitsiades N, Poulaki V, Mitsiades C and Tsokos M: Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. 61:2704–2712. 2001.